Cyril Amarchand Mangaldas (“CAM”) advised Organon & Co. (NYSE: OGN), a global healthcare company, with diverse portfolio across women’s health, biosimilars, and therapies and products for a wide range of conditions and diseases, in its acquisition by Sun Pharmaceutical Holdings USA, Inc., a U.S. subsidiary of Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA), the leading pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.
The transaction team was led by Ruetveij Pandya, Partner; and Saloni Shroff, Partner; with assistance from Abhilasha Malpani, Principal Associate; Sajith Anjickal, Chelsea Sawlani, Neelanshi Gupta, Simran Srivastava, and Shravan Subramanian, Associates.
Rishabh Shroff, Partner (Co-Head – Private Client and Head – International Business Development); provided strategic inputs and guidance.
Meeta Kurpad, Partner; with support from Manasvin Andra, Associate; advised on financing aspects of the transaction.
